ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,099.96
1.02%
Dow Jones
38,239.66
0.40%
US Dollar vs MXN
17.1601
0.00%
Brent Oil
88.165
0.00%
Bitcoin
63,508.49
0.15%
Registration Strip Icon for discussion Regístrate para interactuar en nuestros foros activos para discutir con inversores de ideas afines.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Arvinas Inc (ARVN)

  7. Arvinas Inc (ARVN) Noticias

ARVN Arvinas Inc

32.37
0.77 (2.44%)
26 Abr 2024 - Cerrado
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
Arvinas Inc ARVN NASDAQ Acción Común
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
Upgrade Icon
0.77 2.44% 32.37 16:44:30
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
31.73 31.04 32.72 32.37 31.60
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
24/4/202415:30GLOBEArvinas Appoints Randy Teel, Ph.D., as Chief Business..
11/4/202406:00GLOBEArvinas Enters into a Transaction with Novartis, including a..
18/3/202415:40GLOBEArvinas Appoints Noah Berkowitz, M.D., Ph.D., as Chief..
04/3/202406:00GLOBEArvinas to Participate in Upcoming Investor Conferences
27/2/202417:35EDGAR2Form 4 - Statement of changes in beneficial ownership of..
27/2/202417:34EDGAR2Form 4 - Statement of changes in beneficial ownership of..
27/2/202417:33EDGAR2Form 4 - Statement of changes in beneficial ownership of..
27/2/202417:33EDGAR2Form 4 - Statement of changes in beneficial ownership of..
27/2/202415:46EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
27/2/202406:02EDGAR2Form 8-K - Current report
27/2/202406:00GLOBEArvinas Reports Fourth Quarter and Full Year 2023 Financial..
20/2/202415:06EDGAR2Form 8-K - Current report
20/2/202415:05GLOBEArvinas Announces Chief Financial Officer Transition
20/2/202406:00GLOBEArvinas Announces First-in-Human Dosing of ARV-102, an..
14/2/202407:00GLOBECarrick Therapeutics Announces First Patient Dosed in Phase..
13/2/202419:14EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
06/2/202405:45GLOBEArvinas and Pfizer’s Vepdegestrant (ARV-471) Receives FDA..
01/2/202415:30GLOBEArvinas to Present at 6th Annual Guggenheim Biotechnology..
16/1/202416:01GLOBEArvinas Appoints Jared Freedberg as General Counsel
16/1/202415:03EDGAR2Form S-8 - Securities to be offered to employees in employee..
08/1/202415:39EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/1/202406:45EDGAR2Form 8-K - Current report
08/12/202308:16EDGAR2Form S-3ASR - Automatic shelf registration statement of..
06/12/202306:01EDGAR2Form 8-K - Current report
05/12/202321:52GLOBEArvinas to Host Conference Call and Webcast to Discuss..
05/12/202312:33GLOBEArvinas and Pfizer Announce Interim Data from Phase 1b Trial..
28/11/202316:05GLOBEArvinas and Pfizer Announce Updated Vepdegestrant (ARV-471)..
27/11/202306:11EDGAR2Form 8-K - Current report
27/11/202306:00GLOBEArvinas Announces Oversubscribed $350 Million Private..
07/11/202316:24EDGAR2Form S-3ASR - Automatic shelf registration statement of..
07/11/202315:27EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
07/11/202306:03EDGAR2Form 8-K - Current report
07/11/202306:00GLOBEArvinas Reports Third Quarter 2023 Financial Results and..
02/11/202306:00GLOBEArvinas to Participate in Upcoming Investor Conferences
23/10/202307:30EDGAR2Form 8-K - Current report
22/10/202306:00GLOBEPotential of Arvinas’ PROTAC® AR Degraders Reinforced by..
18/10/202306:00GLOBEArvinas Gives Back to Local Greater New Haven Community in..
15/10/202317:07GLOBEArvinas Announces Upcoming Bavdegalutamide Poster..
15/10/202317:05GLOBEArvinas and Pfizer Announce Upcoming Vepdegestrant (ARV-471)..
01/9/202306:00GLOBEArvinas to Participate in Upcoming Investor Conferences
14/8/202316:27EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/8/202315:09EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
08/8/202306:03EDGAR2Form 8-K - Current report
08/8/202306:00GLOBEArvinas Reports Second Quarter 2023 Financial Results and..
31/7/202315:30GLOBEArvinas and Pfizer Awarded Innovation Passport Designation..
06/7/202308:00GLOBECarrick Therapeutics Announces Clinical Trial Collaboration..
15/6/202315:30GLOBEArvinas Announces Changes to its Board of Directors
08/6/202306:00GLOBEArvinas Announces Interim Data from the ARV-766 Phase 1/2..
05/6/202306:00GLOBEArvinas to Participate in Upcoming Investor Conferences
08/5/202306:00GLOBEArvinas and Pfizer Announce Upcoming Vepdegestrant (ARV-471)..

Su Consulta Reciente

NASDAQ
ARVN
Arvinas
Delayed Upgrade Clock
ADVFN Logo

México
Empresa
Negocios
Popular
Obtener la aplicación

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados